STOCK TITAN

Tenaya Therapeutics (NASDAQ: TNYA) boosts share pool in revised equity plan

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. amended and restated its 2021 Equity Incentive Plan after stockholder approval at the May 27, 2026 annual meeting. The plan now includes a one-time increase of approximately 3% of outstanding shares, adding 6,509,966 shares reserved for equity awards, and revises the annual evergreen provision to a 4% of outstanding shares formula without the prior 4 million share cap. Stockholders also elected three Class II directors to terms ending at the 2029 annual meeting and ratified Deloitte & Touche LLP as independent auditor for the 2026 fiscal year.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
One-time share increase 6,509,966 shares Approx. 3% of outstanding shares added to 2021 plan
Evergreen rate 4% of outstanding shares Annual increase under amended 2021 Equity Incentive Plan
Director vote – Amy Burroughs 87,345,171 for / 2,943,581 withheld Class II director election with 48,606,132 broker non-votes
Auditor ratification support 135,650,321 for Deloitte & Touche LLP for FY ending Dec 31, 2026
Equity plan approval votes for 67,356,607 for Amended and Restated 2021 Equity Incentive Plan
Equity plan votes against 20,575,701 against Stockholder approval of A&R 2021 Equity Incentive Plan
evergreen provision financial
"an amendment to the annual “evergreen” provision to remove the annual limit of 4 million shares"
An evergreen provision is a clause in a financing or contract that automatically renews or replenishes the arrangement unless one party actively cancels it, like a subscription that keeps renewing each term. For investors it matters because it creates predictable, ongoing access to funding or ongoing contractual obligations — helping liquidity and planning — but can also hide long-term commitments or dilution risks if not reviewed.
incentive stock options financial
"and (3) limiting the number of shares that can be issued as incentive stock options under the plan"
Incentive stock options are a type of employee stock option that gives eligible workers the right to buy company shares at a fixed price later on, often below future market value. They matter to investors because they align employee incentives with company performance, can dilute existing ownership when exercised, and create potential tax advantages for option holders if certain holding-time rules are met — think of them as a coupon to buy stock at today’s price with extra tax rules attached.
broker non-votes financial
"Name of Director Nominee | For | Withheld | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Amended and Restated 2021 Equity Incentive Plan financial
"Tenaya Therapeutics, Inc. ... amended and restated its 2021 Equity Incentive Plan"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001858848false00018588482026-05-272026-05-27

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 27, 2026

 

 

Tenaya Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40656

81-3789973

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

171 Oyster Point Boulevard

Suite 500

 

South San Francisco, California

 

94080

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (650) 825-6990

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

TNYA

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Tenaya Therapeutics, Inc. (the “Company”) amended and restated its 2021 Equity Incentive Plan (the “A&R 2021 Equity Incentive Plan”), effective as of May 27, 2026 upon approval by the stockholders of the Company at the Annual Meeting (as defined below).

The amendments to the A&R 2021 Equity Incentive Plan included (1) a one-time increase to the number of shares of common stock reserved for issuance by approximately 3% of the Company’s outstanding shares (6,509,966 shares), (2) an amendment to the annual “evergreen” provision to remove the annual limit of 4 million shares, while maintaining the annual increase at 4% of the Company’s outstanding shares, and (3) limiting the number of shares that can be issued as incentive stock options under the plan.

The material terms of the A&R 2021 Equity Incentive Plan are described in “Proposal No. 3 - Approval of the Tenaya Therapeutics, Inc. Amended and Restated 2021 Equity Incentive Plan” in the Company’s definitive proxy statement on Schedule 14A filed with the United States Securities and Exchange Commission on April 16, 2026, which description is incorporated herein by reference.

The foregoing description of the A&R 2021 Equity Incentive Plan is qualified in its entirety by reference to the text of the A&R 2021 Equity Incentive Plan, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

The Company held its annual meeting of stockholders (the “Annual Meeting”) on May 27, 2026. The matters voted upon at the Annual Meeting and the voting results for each proposal are set forth below.

Proposal 1: Election of Class II Directors

 

Name of Director Nominee

For

Withheld

Broker Non-Votes

Amy Burroughs, M.B.A.

87,345,171

2,943,581

48,606,132

Karah Parschauer, J.D.

86,234,879

4,053,873

48,606,132

Catherine Stehman-Breen, M.D.

87,110,660

3,178,092

48,606,132

Each director nominee was duly elected to serve until the 2029 annual meeting of stockholders and until their successor is duly elected and qualified, subject to earlier resignation or removal.

Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm

 

For

Against

Abstain

Broker Non-Votes

135,650,321

2,023,657

1,220,906

0

The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Proposal 3: Approval of the Company’s Amended and Restated 2021 Equity Incentive Plan

 

For

Against

Abstain

Broker Non-Votes

67,356,607

20,575,701

2,356,444

48,606,132

The stockholders approved the amendment and restatement of the Company’s 2021 Equity Incentive Plan.


Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

 

 

 

Exhibit No.

Description

 

 

10.1

Amended and Restated 2021 Equity Incentive Plan

 

 

104

The cover page of this Current Report on Form 8-K, formatted in inline XBRL.

 

 


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

TENAYA THERAPEUTICS, INC.

By:

/s/ Jennifer Drimmer Rokovich

Jennifer Drimmer Rokovich

General Counsel and Secretary

Date: May 29, 2026

 


FAQ

What did Tenaya Therapeutics (TNYA) change in its 2021 Equity Incentive Plan?

Tenaya Therapeutics amended and restated its 2021 Equity Incentive Plan, adding a one-time 6,509,966 share increase and revising the evergreen feature to a 4% of outstanding shares formula, while capping incentive stock option issuances under the plan.

How many additional Tenaya Therapeutics (TNYA) shares were reserved for equity awards?

The plan now reserves an additional 6,509,966 shares of common stock, described as about 3% of outstanding shares. These shares support future equity-based compensation grants under the Amended and Restated 2021 Equity Incentive Plan.

How did Tenaya Therapeutics (TNYA) stockholders vote on the amended 2021 Equity Incentive Plan?

Stockholders approved the amended and restated 2021 Equity Incentive Plan with 67,356,607 votes for, 20,575,701 against, and 2,356,444 abstentions, along with 48,606,132 broker non-votes recorded for this proposal at the annual meeting.

Which directors were elected at the Tenaya Therapeutics (TNYA) 2026 annual meeting?

Stockholders elected Amy Burroughs, Karah Parschauer, and Catherine Stehman-Breen as Class II directors. Each will serve until the 2029 annual meeting and until a successor is elected and qualified, subject to earlier resignation or removal.

Who is Tenaya Therapeutics (TNYA) independent auditor for fiscal 2026?

Stockholders ratified Deloitte & Touche LLP as Tenaya Therapeutics’ independent registered public accounting firm for the year ending December 31, 2026, with 135,650,321 votes for, 2,023,657 against, and 1,220,906 abstentions and no broker non-votes.

What is the revised evergreen provision in Tenaya Therapeutics (TNYA) equity plan?

The amended plan keeps the annual increase at 4% of outstanding shares but removes the prior 4 million share cap. This evergreen feature automatically refreshes the pool of shares available for future equity awards each year.

Filing Exhibits & Attachments

2 documents